Phibro Animal Health (NASDAQ:PAHC) Upgraded at StockNews.com

StockNews.com upgraded shares of Phibro Animal Health (NASDAQ:PAHC) from a buy rating to a strong-buy rating in a report issued on Tuesday morning.

A number of other brokerages also recently issued reports on PAHC. JPMorgan Chase & Co. began coverage on shares of Phibro Animal Health in a research report on Tuesday, September 10th. They issued a “neutral” rating and a $22.00 price objective for the company. Barclays lifted their target price on shares of Phibro Animal Health from $13.00 to $20.00 and gave the stock an “underweight” rating in a research note on Tuesday. Finally, Bank of America upped their price target on shares of Phibro Animal Health from $13.00 to $15.00 and gave the company an “underperform” rating in a research note on Friday, August 30th. Three analysts have rated the stock with a sell rating, one has assigned a hold rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Phibro Animal Health presently has an average rating of “Hold” and an average price target of $16.50.

Phibro Animal Health Trading Down 0.5 %

Shares of PAHC traded down $0.12 during trading hours on Tuesday, hitting $24.78. 17,943 shares of the stock were exchanged, compared to its average volume of 156,935. The firm has a market capitalization of $1.00 billion, a P/E ratio of 57.91, a price-to-earnings-growth ratio of 0.66 and a beta of 0.51. The company has a debt-to-equity ratio of 1.81, a current ratio of 3.23 and a quick ratio of 1.69. Phibro Animal Health has a fifty-two week low of $9.49 and a fifty-two week high of $25.98. The business has a 50-day moving average of $22.68 and a 200-day moving average of $19.65.

Phibro Animal Health (NASDAQ:PAHC) last posted its quarterly earnings results on Wednesday, August 28th. The company reported $0.41 earnings per share for the quarter, beating the consensus estimate of $0.34 by $0.07. The firm had revenue of $273.16 million during the quarter, compared to the consensus estimate of $262.44 million. Phibro Animal Health had a net margin of 1.67% and a return on equity of 21.59%. On average, research analysts expect that Phibro Animal Health will post 1.59 EPS for the current year.

Phibro Animal Health Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, December 18th. Stockholders of record on Wednesday, November 27th will be given a dividend of $0.12 per share. The ex-dividend date of this dividend is Wednesday, November 27th. This represents a $0.48 dividend on an annualized basis and a dividend yield of 1.94%. Phibro Animal Health’s dividend payout ratio (DPR) is currently 111.63%.

Insiders Place Their Bets

In other news, Director E Thomas Corcoran bought 5,000 shares of the company’s stock in a transaction that occurred on Wednesday, September 4th. The stock was bought at an average price of $20.02 per share, for a total transaction of $100,100.00. Following the transaction, the director now directly owns 25,000 shares of the company’s stock, valued at $500,500. This represents a 25.00 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 50.07% of the company’s stock.

Institutional Investors Weigh In On Phibro Animal Health

A number of hedge funds have recently made changes to their positions in the business. BNP Paribas Financial Markets boosted its holdings in shares of Phibro Animal Health by 13.5% during the first quarter. BNP Paribas Financial Markets now owns 83,179 shares of the company’s stock worth $1,076,000 after purchasing an additional 9,892 shares during the period. Illinois Municipal Retirement Fund raised its holdings in Phibro Animal Health by 7.2% in the first quarter. Illinois Municipal Retirement Fund now owns 11,430 shares of the company’s stock worth $148,000 after buying an additional 765 shares during the last quarter. Acadian Asset Management LLC increased its position in shares of Phibro Animal Health by 32.8% during the first quarter. Acadian Asset Management LLC now owns 675,207 shares of the company’s stock valued at $8,726,000 after acquiring an additional 166,776 shares in the last quarter. Price T Rowe Associates Inc. MD raised its holdings in Phibro Animal Health by 7.4% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 15,393 shares of the company’s stock worth $200,000 after acquiring an additional 1,063 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. raised its holdings in Phibro Animal Health by 56.0% in the 1st quarter. Jacobs Levy Equity Management Inc. now owns 79,667 shares of the company’s stock worth $1,030,000 after acquiring an additional 28,584 shares during the last quarter. 99.34% of the stock is currently owned by institutional investors.

About Phibro Animal Health

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.